Key facts
- This page summarizes Anchorage Capital Advisors, L.P.'s Form 3 filing for Cano Health, Inc..
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 08 Jul 2024, 16:13.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
No transaction description listed
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No transaction description listed
No transaction description listed
No transaction description listed
Additional SEC filing notes
Footnote F1
These securities are held for the accounts of funds managed by Anchorage Collateral Management, L.L.C., a relying adviser of Anchorage Capital Advisors, L.P. ("Capital Advisors"), its sole member.
Footnote F2
These securities are held for the account of a fund managed by Anchorage Opportunities Advisor, L.L.C., a relying adviser of Capital Advisors, its sole member.
Footnote F3
These securities are held for the accounts of funds managed by Anchorage Strategies Advisor, L.L.C., a relying adviser of Capital Advisors, its sole member.
Footnote F4
Anchorage Advisor Holdings Management, L.P. ("Holdings Management") is the majority owner of Capital Advisors. Anchorage Advisor Holdings GP, L.L.C. ("Holdings GP") is the sole general partner of each of Capital Advisors and Holdings Management. Mr. Baron and Mr. Gournay are co-managing members of Holdings GP. Each of Capital Advisors, Holdings Management, Holdings GP, Mr. Baron and Mr. Gournay may therefore be deemed to beneficially own the securities reported herein, and each disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that it or he is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F5
These warrants will expire on June 28, 2029, or earlier upon the occurrence of certain events as set forth in the related warrant agreement (the "Warrant Agreement").
Footnote F6
These warrants have an initial exercise price of $25.30 per share of Common Stock, subject to certain customary adjustments as set forth in the Warrant Agreement.